HomeCompareCPHRF vs JEPQ

CPHRF vs JEPQ: Dividend Comparison 2026

CPHRF yields 15.38% · JEPQ yields 11.47%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPHRF wins by $9.0K in total portfolio value
10 years
CPHRF
CPHRF
● Live price
15.38%
Share price
$13.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.8K
Annual income
$3,973.98
Full CPHRF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.47%
Share price
$53.77
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.8K
Annual income
$2,269.18
Full JEPQ calculator →

Portfolio growth — CPHRF vs JEPQ

📍 CPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPHRFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPHRF + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPHRF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPHRF
Annual income on $10K today (after 15% tax)
$1,307.69/yr
After 10yr DRIP, annual income (after tax)
$3,377.88/yr
JEPQ
Annual income on $10K today (after 15% tax)
$974.55/yr
After 10yr DRIP, annual income (after tax)
$1,928.80/yr
At 15% tax rate, CPHRF beats the other by $1,449.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPHRF + JEPQ for your $10,000?

CPHRF: 50%JEPQ: 50%
100% JEPQ50/50100% CPHRF
Portfolio after 10yr
$50.3K
Annual income
$3,121.58/yr
Blended yield
6.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CPHRF right now

CPHRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
8.2
Piotroski
8/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPHRF buys
0
JEPQ buys
0
No recent congressional trades found for CPHRF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPHRFJEPQ
Forward yield15.38%11.47%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$54.8K$45.8K
Annual income after 10y$3,973.98$2,269.18
Total dividends collected$26.9K$17.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CPHRF vs JEPQ ($10,000, DRIP)

YearCPHRF PortfolioCPHRF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$12,238$1,538.46$11,967$1,146.53+$271.00CPHRF
2$14,855$1,759.66$14,216$1,268.02+$639.00CPHRF
3$17,891$1,996.12$16,774$1,392.20+$1.1KCPHRF
4$21,390$2,246.80$19,667$1,518.21+$1.7KCPHRF
5$25,398$2,510.50$22,925$1,645.21+$2.5KCPHRF
6$29,961$2,785.88$26,578$1,772.40+$3.4KCPHRF
7$35,130$3,071.47$30,656$1,899.04+$4.5KCPHRF
8$40,955$3,365.74$35,194$2,024.45+$5.8KCPHRF
9$47,489$3,667.11$40,228$2,148.01+$7.3KCPHRF
10$54,787$3,973.98$45,796$2,269.18+$9.0KCPHRF

CPHRF vs JEPQ: Complete Analysis 2026

CPHRFStock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Full CPHRF Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this CPHRF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPHRF vs SCHDCPHRF vs JEPICPHRF vs OCPHRF vs KOCPHRF vs MAINCPHRF vs XYLDCPHRF vs QYLDCPHRF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.